patients complying with cancer for whom is mandatory to know the replicative cellular activty MedDRA version: 14.1 Level: SOC Classification code 10022891 Term: Investigations System Organ Class: 10022891 - Investigations MedDRA version: 14.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Product Name: F18 FLT
Product Code: NA
Pharmaceutical Form: Radiopharmaceutical precursor
Other descriptive name: FLT F18
Concentration unit: MBq megabecquerel(s)
Concentration type: equal
Concentrati
Sponsors
CENTRO DI RIFERIMENTO ONCOLOGICO DI BASILICATA
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: patients for whom is mandatory to know cellular replication and to monitor therpy efficacy early Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 70 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 30
Exclusion criteria
Exclusion criteria: • Age 90 yrs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Impact of F18 FLT PET/CT for replicative evaluation in staging, restaging and therapy assessment of tumours rather than energetic metabolism;Secondary Objective: correlation to angiogenetic markers and EGFR mutations;Primary end point(s): Diagnostic accuracy of F18 FLT PET/CT;Timepoint(s) of evaluation of this end point: 48 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): metastatic assessment and correlation to neoplastic markers;Timepoint(s) of evaluation of this end point: 48 months | — |
Countries
Italy
Contacts
Public ContactMedicina Nucleare
IRCCS CROB centro di riferimento oncologico di basilicata
Outcome results
None listed